Jan Gillespie Wagner, MD
Interventional Pain Medicine · Greeley, CONPI 1043293921
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.2% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 60.3% of it on its own, with 10 other manufacturers making up the rest.
Across 78 payments — averaging $22.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Pfizer$196
- Merz Pharmaceuticals, LLC$169
- Amgen$143
- Merz North America, Inc.$47
- Teva Pharmaceuticals USA, Inc.$40
- plus $115 from 5 others
What the payments were for
- Food & beverage$1,70495%
- Education$855%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 58 | $1,079 |
| Pfizer | 6 | $196 |
| Merz Pharmaceuticals, LLC | 4 | $169 |
| Amgen | 2 | $143 |
| Merz North America, Inc. | 2 | $47 |
| Teva Pharmaceuticals USA, Inc. | 1 | $40 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $28 |
| Si-bone, Inc. | 1 | $26 |
| Johnson & Johnson | 1 | $25 |
| Lilly USA, LLC | 1 | $19 |
| Indivior Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,789 in reported general payments places this provider in the 55th percentile of 25 interventional pain medicine providers in Colorado.
See all interventional pain medicine providers in Colorado →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine | 22 | $5,455 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 48 | $1,608 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 39 | $768 |
| Gabapentin | 33 | $461 |
| Oxycodone Hcl | 19 | $422 |
| Hydromorphone Hcl | 15 | $313 |
| Morphine Sulfate ErMorphine Sulfate | 11 | $266 |
| Pregabalin | 11 | $185 |
| Meloxicam | 17 | $94 |
| Tramadol Hcl | 18 | $62 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Greeley
- Chloe McCullochGreeley$340
- Phillip AbstonGreeley$14
- Bradley VilimsLakewood$978K
- George GirardiFort Collins$220K
- Michael BrownFort Collins$34K
- Shaun GabrielDenver$19K
- Tomas SalazarAurora$10K
- Eduardo CarreraCastle Rock$7K
- Jason KrutschLakewood$5K
- James BainbridgeGreenwood Village$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.